Accurate determination of vismodegib (VISMO), a Hedgehog pathway inhibitor approved for the management of basal cell carcinoma and other malignancies, is essential for pharmacokinetic assessment, dose optimization, and therapeutic drug monitoring.
Alaseem et al. (Thu,) studied this question.